Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 4/20 | 0.56 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.54 |
| ▸ | CES2 | O00748 | 2/20 | 0.48 |
| ▸ | CES1 | P23141 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylene Chloride SCHEMBL28191198 | 0.91 | ERN1 (0.48) | ERN1NFE2L2CES2CES1KDM4E | |
| SCHEMBL3430702 | 0.86 | NFE2L2 (0.52) | ERN1NFE2L2CES2CES1KDM4E | |
| SCHEMBL4363014 | 0.82 | ERN1 (0.46) | ERN1NFE2L2CES2CES1KDM4E | |
| SCHEMBL29957006 | 0.82 | ERN1 (0.46) | ERN1NFE2L2CES2CES1KDM4E | |
| SCHEMBL28217646 | 0.82 | NFE2L2 (0.44) | ERN1NFE2L2KDM4EALDH1A1 | |
| SCHEMBL7553407 | 0.80 | NFE2L2 (0.46) | ERN1NFE2L2ALDH1A1 | |
| SCHEMBL29824365 | 0.80 | NFE2L2 (0.54) | ERN1NFE2L2CES2CES1KDM4E | |
| Water SCHEMBL28915146 | 0.80 | ERN1 (0.45) | ERN1NFE2L2CES2CES1KDM4E | |
| SCHEMBL96915 | 0.80 | NFE2L2 (0.54) | ERN1NFE2L2CES2CES1KDM4E | |
| SCHEMBL5252638 | 0.79 | NFE2L2 (0.58) | ERN1NFE2L2CES2CES1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1686 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117143598-B | High-entropy carbon quantum dot nanomaterial and preparation method and application thereof | 中南大学 | 2024-11-08 | — | — | CN | claimed |
| CN-118879789-A | Method for preparing 2, 5-difluoro cinnamaldehyde by using benzaldehyde lyase | 浙江工业大学 | 2024-11-01 | — | — | CN | claimed |
| CN-118496215-A | Polyhydroxylated onium derivative with disubstituted benzene ring, preparation method and medical application thereof | 中国药科大学 | 2024-08-16 | — | — | CN | claimed |
| CN-118459420-A | Thiazolinone compound containing multiple halogen atoms and preparation method thereof | 南京工业大学 | 2024-08-09 | — | — | CN | claimed |
| CN-118459422-A | Thiazole thiazolinone compound containing multiple halogen atoms and preparation method thereof | 南京工业大学 | 2024-08-09 | — | — | CN | claimed |
| CN-221287823-U | Difluorobenzaldehyde ethylene glycol fine chemical production line | 江苏广域化学有限公司 | 2024-07-09 | — | — | CN | claimed |
| CN-117624148-A | Polyhydroxy sulfonium salt derivative with disubstituted benzene ring, preparation method and medical application thereof | 中国药科大学 | 2024-03-01 | — | — | CN | claimed |
| CN-117143598-A | High-entropy carbon quantum dot nanomaterial and preparation method and application thereof | 中南大学 | 2023-12-01 | — | — | CN | claimed |
| CN-115092909-B | High-concentration fluorine-doped carbon dot and preparation method thereof | 中南大学 | 2023-06-09 | — | — | CN | claimed |
| CN-113321800-B | Application of selective laser sintering by taking polyether-ether-ketone prepared from tetramethyl guanidine tetrafluoroborate as raw material | 江汉大学 | 2023-05-23 | — | — | CN | claimed |
| US-20050113574-A1 | Methods and compositions comprising diamines as new anti-tubercular therapeutics | SEQUELLA, INC. | 2005-05-26 | — | — | US | claimed |
| WO-2005046685-A1 | SUBSTITUTED PIPERIDINES FOR THE TREATMENT OF METABOLIC SYNDROME | ASTRAZENECA AB (SE) | 2005-05-26 | — | — | WO | claimed |
| WO-2005034857-A2 | METHODS AND COMPOSITIONS COMPRISING DIAMINES AS NEW ANTI-TUBERCULAR THERAPEUTICS | SEQUELLA, INC. (US) | 2005-04-21 | — | — | WO | claimed |
| US-20040132807-A1 | Aurones as telomerase inhibitors | PHARMACIA ITALIA SPA (IT) | 2004-07-08 | — | — | US | claimed |
| EP-1422218-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2004-05-26 | — | — | EP | claimed |
| EP-1381359-A1 | AURONES AS TELOMERASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-01-21 | — | — | EP | claimed |
| WO-2002083123-A1 | AURONES AS TELOMERASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2002-10-24 | — | — | WO | claimed |
| US-20020146633-A1 | FLUORINATED AROMATIC ACETAL POLYMERS AND PHOTOSENSITIVE COMPOSITIONS CONTAINING SUCH POLYMERS | KODAK POLYCHROME GRAPHICS L.L.C. | 2002-10-10 | — | — | US | claimed |
| US-6458503-B1 | BLEND WITH DIAZO RESIN; LITHOGRAPHIC PRINTING PLATES; PHOTOPOLYMERIZATION AND CROSSLINKING | KODAK POLYCHROME GRAPHICS LLC | 2002-10-01 | — | — | US | claimed |
| WO-2002073315-A1 | FLUORINATED AROMATIC ACETAL POLYMERS AND PHOTOSENSITIVE COMPOSITIONS CONTAINING SUCH POLYMERS | KODAK POLYCHROME GRAPHICS COMPANY, LTD. (US) | 2002-09-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113574-A1 | Methods and compositions comprising diamines as new anti-tubercular therapeutics | C5, DDC, SAT1 | ERN1 927/4885NFE2L2 3853/4885CES2 3578/4885 |
| US-20040132807-A1 | Aurones as telomerase inhibitors | TERT, TERF2, TERF2IP | ERN1 572/4885NFE2L2 2212/4885CES2 4303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.